– USA, CA – Global Blood Therapeutics, Inc. (NASDAQ: GBT) today announced the appointment of Dr. Alexis Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease expert, to its Board of Directors.
Dr. Thompson, who brings decades of experience in clinical research, patient care, leadership, and advocacy in hematology, will serve on the board’s research and development committee.
“We’re thrilled to welcome Alexis to our board as we continue to pursue the transformation of care in sickle cell disease,” said CEO Dr. Ted Love. “Her deep expertise in blood disorders and her commitment to addressing health equity will be invaluable as GBT continues to expand its leadership both in the United States and globally. We look forward to her extensive knowledge and innovative thought leadership that will add to our board’s diverse backgrounds and breadth of experience.”
About Dr. Alexis Thompson
Dr. Alexis Thompson, a board-certified pediatric hematologist, is head of the Hematology Section and director of the Comprehensive Thalassemia Program at the Ann and Robert H. Lurie Children’s Hospital of Chicago, where she also serves as the A. Watson and Sarah Armour Endowed Chair for Childhood Cancer and Blood Disorders. Also, Dr. Thompson is associate director for equity and minority health at the Robert H. Lurie Cancer Center and Northwestern University Feinberg School of Medicine. She has served on national advisory committees for governmental agencies as well as non-profit organizations focused on improving healthcare access, increasing workforce diversity, and reducing health disparities. In 2018, Dr. Thompson served as president of the American Society of Hematology and continues to serve on ASH’s Sickle Cell Disease Task Force.
“I’ve always wanted to make a difference, and GBT is a company that has been at the forefront of making very substantial progress on improving the lives of patients living with serious blood disorders, particularly sickle cell disease. The GBT mission to make this devastating disease a well-managed condition is one that I eagerly support,” said Dr. Alexis Thompson. “I look forward to serving on GBT’s board as the company advances innovative therapies for different facets of SCD and potentially other orphan blood diseases, improving overall care for underserved patients.”
Dr. Thompson is an investigator on multicenter clinical trials as well as her own institutional clinical studies in SCD and thalassemia. She has been a leader in multicenter collaborations, such as the National Heart, Lung, and Blood Institute’s Sickle Cell Disease Implementation Consortium, and has received numerous awards recognizing her expertise in teaching and clinical care. Dr. Thompson received her medical degree from Tulane University, earned her master’s in public health degree from the University of California, Los Angeles, and completed her postgraduate training at Children’s Hospital Los Angeles and the Children’s Hospital of Philadelphia.
About Global Blood Therapeutics
Global Blood Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601, the company’s next-generation hemoglobin S polymerization inhibitor. Also, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
For more information: https://www.gbt.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
